Vectus Biosystems Ltd

VBS

Company Profile

  • Business description

    Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company has developed and patented various novel compounds for the treatment of chronic fibrosis, including heart, kidney, liver, and lung fibrosis. Its drug candidate VB0004, is aimed at inhibiting and reversing the loss of functional tissue due to fibrosis, is in its human trials phase. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. It operates in one segment, being pharmaceutical research and development.

  • Contact

    26-34 Dunning Avenue
    Unit 5, Ground Floor
    Rosebery
    SydneyNSW2018
    AUS

    T: +61 283441300

    https://www.vectusbiosystems.com.au

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2025

    Employees

Stocks News & Analysis

stocks

Ask the analyst: Can this big Covid loser scale its former heights?

Corporate Travel Management saw its profits fall through the floor during the pandemic. Our analyst Brian Han answers a reader question on what might be next.
stocks

Our view of BHP after reporting sales volumes

First half results largely met our expectations.
stocks

The fight for Insignia continues

Numerous acquisition proposals vindicate Insignia's improved earnings momentum.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,660.4031.300.36%
CAC 407,927.6235.010.44%
DAX 4021,394.9316.60-0.08%
Dow JONES (US)44,424.25140.82-0.32%
FTSE 1008,502.3562.85-0.73%
HKSE20,066.19365.631.86%
NASDAQ19,954.3099.38-0.50%
Nikkei 22539,931.9826.89-0.07%
NZX 50 Index13,024.7035.38-0.27%
S&P 5006,101.2417.47-0.29%
S&P/ASX 2008,408.9030.200.36%
SSE Composite Index3,252.6322.460.70%

Market Movers